NCT00105157

Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)

Multicenter Study to Evaluate the Safety and Efficacy of MK0518 in Combination With An Optimized Background Therapy (OBT), Versus OBT Alone, in HIV-Infected Patients With Documented Resistance

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 179 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will investigate the safety and efficacy of different doses of an investigational drug (MK0518) as a therapy for HIV-infected patients failing current antiretroviral therapies.

Conditions

• HIV Infections
• Acquired Immunodeficiency Syndrome

Interventions

Type	Name	Description
DRUG	Comparator: MK0518	MK0518 oral tablets 200 mg b.i.d, for 24 weeks
DRUG	MK0518	MK0518 oral tablets 400 mg b.i.d, for 24 weeks
DRUG	MK0518	MK0518 oral tablets 600 mg b.i.d, for 24 weeks
DRUG	Placebo	Placebo to MK0518, oral tablet b.i.d, for 24 weeks

Timeline

• Start date: 2005-03-01
• Primary completion: 2006-10-01
• Completion: 2009-07-01
• First posted: 2005-03-09
• Last updated: 2015-12-04
• Results posted: 2010-04-12